PFE

Pfizer Inc. faces a significant loss of exclusivity wall, but the biopharma has a new drug pipeline and cost-cutting plans to cover most of the sales hits. PFE guided 2026 revenues to $61.5B, with COVID-19 revenues now minimal and high single-digit growth projected starting in 2029. The company has another major cost reduction plan for savings of up to $4B to offset most gross profit losses from LoEs, supporting stable EPS near $2.90 through 2028.

AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.

A fat dividend yield can signal a screaming buy or a slow-motion disaster, and the difference hides in coverage math most investors never check.

Viking Therapeutics NASDAQ: VKTX stock jumped 36% on Sept. 22. The catalyst was new maintenance data for VK2735, its GLP-1/GIP obesity candidate, which showed that patients maintained most of their weight loss after switching from weekly shots to every-other-week or monthly dosing.

Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.

Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions.

AT&T, Verizon, and Pfizer all trade under $50 a share, but a low entry price and genuine value are two very different things, and only one of these three high-yield names carries a coverage story that should make income investors

Pfizer is upgraded to buy, supported by a low valuation, strong free cash flow, and a high 6.2% dividend yield. PFE delivered a Q2 double beat, raised full-year revenue guidance, and benefits from pipeline progress, though COVID-19 product sales guidance was trimmed. Technical momentum is building, with a golden cross and bullish rounded bottom pattern, but resistance remains near $30.

Pfizer Inc. (PFE) Presents at U.S. All Stars Conference Transcript

Pfizer remains a Buy, with valuation reflecting LOE risks and attractive risk-reward as the company executes on post-LOE growth strategies. PFE delivered a strong quarter, raising revenue guidance to $61.5B, driven by non-COVID portfolio strength and past acquisitions. Operational efficiency programs target $9.7B in cost savings through 2029, supporting ongoing R&D investment, deleveraging, and a robust 6.22% dividend yield.